Replies to post #556716 on NorthWest Biotherapeutics Inc (NWBO)

[jdheart101]

That’s why wall street hates us

[vator]

You are wrong on timing but with no input from management any speculation is viable.

[dennisdave]

Regardless of whether or not you like NVCR's product, their timeline and path outlined in today's PR is standard practice.

agreed

NWBO's timeline is out of the ordinary.

agreed

I understand and appreciate they wanted a reputable journal first and as a smaller biotech, they will understandably need more time,

I dont understand it, not anymore. What have they achieved? They said it was to thwart the bears. It hasnt. They said it was to support the short attacks. It hasnt. They should have announced topline 6 months after datalock and then after that started working full-time getting the MAA approval with ANOTHER CDMO with Cognate. Then after the request for approval was submitted come with JA and work towards MIA for Toucan subsidiary Advent. We would be now sitting at 4-5$ if not more SP.

but this is getting out of hand.

agreed

NWBO still have a ways to go until they submit an app, my guess is approvals in mid to late 2024. I hope I'm wrong.

I hope that too

[Poor Man -]

Honestly, given the trajectory of everything and how painfully slow any progress has been made since DL, combined with the protracted outlook, I just can’t believe they wouldn’t substantially hand over the reins to a BP partner with the eventual goal of selling the entire company.

I joke about this stuff, but it’s not a healthy situation for the company, patients and investors to be in.